drugset / Trial / NCT00762736

Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus

NCT00762736

Phase 2 Completed 704 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the efficacy of pioglitazone, once daily (QD), combined with azilsartan in the treatment of subjects with Type 2 Diabetes Mellitus.

Timeline

Start
2004-07
Primary completion
2005-10
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan Unknown 5 mg Oral
Subject Azilsartan Unknown 40 mg Oral
Subject Pioglitazone Small molecule 15 mg Oral
Subject Pioglitazone Small molecule 45 mg Oral